---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000008"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:52:35.975204+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moderna Q4 net income down 70% to $1.5B; FY2022 revenue $19.3B; reiterates $5B COVID sales for 2023

## Summary
- Q4 2022 revenue $5.1B (down 29% YoY from $7.2B); GAAP diluted EPS $3.61 (down 68% from $11.29).
- Full-year 2022 revenue $19.3B (up 4% from $18.5B); GAAP net income $8.4B (down 31% from $12.2B); diluted EPS $20.12.
- Cost of sales surged to 39% of product sales in Q4 (from 14% YoY) due to $297M inventory write-downs, $281M purchase commitment losses, $376M unutilized capacity charges.
- R&D spending increased 87% to $1.2B in Q4; full-year R&D $3.3B (up 65%); 2023 R&D guidance $4.5B.
- Juan Andres, President of Strategic Partnerships, to retire in May 2023; Jerh Collins joined as CTOO in October 2022.

## SEC filing metadata
- accession: 0001682852-23-000008
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/0001682852-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/mrna-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000008
- JSON: https://secwatch.observer/filing/0001682852-23-000008.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000008.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue $19.3 billion, net income $8.4 billion, EPS $20.12. Guidance reaffirmed.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $19.3 billion
  - Net income: $8.4 billion
  - EPS: $20.12
  - Guidance: reaffirmed
  - Result: reported results
  source text: Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/0001682852-23-000008-index.htm
- Earnings Releases
  Moderna, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $5.1 billion, net income $1.5 billion, EPS $3.61. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $5.1 billion
  - Net income: $1.5 billion
  - EPS: $3.61
  - Guidance: reaffirmed
  - Result: reported results
  source text: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000008/0001682852-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.